Blog | BioInformant

How to find unique market opportunities by stem cell type

May 15, 2017 By Cade Hildreth, Founder & President Leave a Comment

As the first and only market research firm to specialize in the stem cell industry, BioInformant’s 175-page global strategic report “Stem Cell Research Products – Opportunities, Tools, and Technologies” evaluates strategies across the stem cell product spectrum, with emphasis on opportunities for research product development.

It explores unique market opportunities by stem cell type, including mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and more. [Read more…]

Longeveron Begins Enrollment of Second Cohort of Phase 1 Alzheimer’s Disease Trial

May 10, 2017 By Cade Hildreth, Founder & President Leave a Comment

MIAMI, May 10, 2017 — Longeveron, a regenerative medicine company, announced that their Phase 1 Alzheimer’s disease trial will proceed with enrollment at the recommendation of an independent Data Monitoring Committee (DMC) which reviewed data from the trial’s safety run-in phase.

The clinical trial is designed to assess the safety, tolerability and efficacy of intravenous infusion of two different doses of Longeveron mesenchymal stem cells (LMSCs) compared to placebo. The DMC reviewed safety data from a five-patient run-in phase where subjects diagnosed with Alzheimer’s disease were given a single infusion of either LMSCs or placebo. Longeveron now has the green light to continue the trial.

[Read more…]

Pluristem Announces Promising Results from Non-Human Primate Pilot Study of PLX-R18 in Acute Radiation Syndrome

May 8, 2017 By Cade Hildreth, Founder & President Leave a Comment

All PLX-treated groups showed improvements in survival rates compared to untreated groups
PLX-R18 cells did not increase leukocyte levels in non-irradiated NHPs, indicating no requirement to determine levels of radiation exposure prior to administration
Data will inform a pivotal trial that could support marketing authorization under the FDA’s Animal Rule regulatory pathway

[Read more…]

Exopharm to commercialize a new type of nano-drug for regenerative medicine

May 5, 2017 By Cade Hildreth, Founder & President Leave a Comment

May 5, 2017, Melbourne, Australia — A private Australian biotechnology company called Exopharm has announced its investment to bring a completely new type of drug called exosomes into local clinical trials.

Exopharm is founded and backed by Dr Ian Dixon, the Melbourne-based technology innovator behind an ASX-listed cell therapy company, the anisina anticancer drug and the Altnia Group incubator. After more than 3 years of secret R&D, Altnia is spinning Exopharm out as a specialist company to translate the promising scientific research around exosomes into routine clinical use worldwide for regenerative medicine. Exopharm will build on its patented purification technology called LEAP to make its proprietary exomeres in large scale and at low cost. [Read more…]

RoosterBio Launches Xeno-Free hMSC Cell Banks to Advance Stem Cell Biomanufacturing

May 4, 2017 By Cade Hildreth, Founder & President Leave a Comment

RoosterBio Launches the Regenerative Medicine Industry’s First Xeno-Free hMSC Cell Banks to Advance and Simplify Stem Cell Biomanufacturing

FREDERICK, MARYLAND, May 04, 2017–At a CAGR of 23.2% and estimated revenue of $68B by 2020, the Regenerative Medicine (“RM”) industry continues to call for new tools designed to accelerate this aggressive growth. Based on strong RM market demand, RoosterBio Inc today announces the launch of xeno-free (“XF”) human bone-marrow derived mesenchymal stem/stromal cell (hMSC) products.

[Read more…]